+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Western blot analysis using HPRT1 mouse mAb against Hela (1), A431 (2), A549 (3) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of Hela cells using HPRT1 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human kidney tissues using HPRT1 mouse mAb with DAB staining.    

  
  

The KLK7 antibody targets kallikrein-related peptidase 7 (KLK7), a serine protease encoded by the *KLK7* gene. Part of the human tissue kallikrein family, KLK7 plays a role in desquamation (skin shedding) by cleaving extracellular matrix proteins like corneodesmosomes, aiding epidermal renewal. It is primarily expressed in skin, but also detected in ovarian, breast, and gastrointestinal tissues. Dysregulated KLK7 activity is linked to pathological conditions, including psoriasis, atopic dermatitis, and cancer progression, where its overexpression may promote tumor invasion and metastasis by degrading adhesion molecules or activating protease-activated receptors (PARs).

KLK7 antibodies are essential tools for detecting protein expression in research and diagnostics. Monoclonal and polyclonal variants are used in techniques like immunohistochemistry, ELISA, and Western blot to study KLK7's role in disease mechanisms. Therapeutic applications are under exploration, with inhibitors and antibody-based strategies aiming to modulate KLK7 activity in inflammatory skin disorders or cancers. However, challenges remain in specificity and off-target effects due to structural similarities among kallikreins. Ongoing studies focus on refining antibody design to improve clinical relevance, positioning KLK7 as both a biomarker and a potential therapeutic target.